| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 54 | 2025 | 825 | 10.290 |
Why?
|
| Myelodysplastic Syndromes | 41 | 2026 | 379 | 8.510 |
Why?
|
| Myeloproliferative Disorders | 29 | 2025 | 146 | 7.100 |
Why?
|
| Bone Marrow | 44 | 2025 | 408 | 5.670 |
Why?
|
| Leukemia | 22 | 2023 | 300 | 5.040 |
Why?
|
| Mutation | 56 | 2026 | 4265 | 3.680 |
Why?
|
| Immunophenotyping | 54 | 2023 | 224 | 2.970 |
Why?
|
| Tumor Suppressor Protein p53 | 17 | 2026 | 453 | 2.960 |
Why?
|
| Leukemia, Myeloid | 19 | 2016 | 240 | 2.850 |
Why?
|
| Chromosome Aberrations | 26 | 2026 | 348 | 2.840 |
Why?
|
| Translocation, Genetic | 26 | 2016 | 245 | 2.590 |
Why?
|
| Lymphoma, T-Cell | 16 | 2022 | 60 | 2.570 |
Why?
|
| Hematologic Neoplasms | 16 | 2025 | 372 | 2.440 |
Why?
|
| World Health Organization | 18 | 2025 | 121 | 2.110 |
Why?
|
| Splenic Neoplasms | 8 | 2020 | 17 | 2.110 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 13 | 2025 | 422 | 2.080 |
Why?
|
| Humans | 289 | 2026 | 93132 | 1.940 |
Why?
|
| Lymphoma, Follicular | 15 | 2016 | 73 | 1.890 |
Why?
|
| Lymphoma, B-Cell | 21 | 2022 | 107 | 1.850 |
Why?
|
| Myelodysplastic-Myeloproliferative Diseases | 7 | 2025 | 12 | 1.760 |
Why?
|
| Lymphoma | 14 | 2022 | 247 | 1.690 |
Why?
|
| Neoplasm Proteins | 12 | 2020 | 537 | 1.680 |
Why?
|
| Biomarkers, Tumor | 37 | 2017 | 1660 | 1.670 |
Why?
|
| Pancytopenia | 4 | 2016 | 18 | 1.650 |
Why?
|
| Prognosis | 48 | 2026 | 3890 | 1.600 |
Why?
|
| Herpesvirus 4, Human | 13 | 2020 | 122 | 1.500 |
Why?
|
| Leukemia, Erythroblastic, Acute | 4 | 2022 | 28 | 1.490 |
Why?
|
| Aged, 80 and over | 70 | 2026 | 7039 | 1.470 |
Why?
|
| Middle Aged | 135 | 2026 | 27535 | 1.460 |
Why?
|
| Mastocytosis | 5 | 2025 | 14 | 1.430 |
Why?
|
| Immunohistochemistry | 53 | 2022 | 1786 | 1.390 |
Why?
|
| Male | 164 | 2026 | 44355 | 1.380 |
Why?
|
| Bone Marrow Examination | 10 | 2020 | 40 | 1.350 |
Why?
|
| Leukemia, Biphenotypic, Acute | 3 | 2022 | 5 | 1.330 |
Why?
|
| Aged | 106 | 2026 | 20395 | 1.330 |
Why?
|
| Acute Disease | 23 | 2023 | 838 | 1.320 |
Why?
|
| Eosinophilia | 5 | 2025 | 87 | 1.300 |
Why?
|
| Adult | 122 | 2026 | 27849 | 1.260 |
Why?
|
| Female | 153 | 2026 | 48542 | 1.240 |
Why?
|
| Antigens, CD | 28 | 2014 | 476 | 1.220 |
Why?
|
| Mast Cells | 5 | 2025 | 96 | 1.220 |
Why?
|
| Hodgkin Disease | 11 | 2020 | 144 | 1.160 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 5 | 2020 | 23 | 1.150 |
Why?
|
| Lymphoma, Non-Hodgkin | 12 | 2015 | 260 | 1.150 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 6 | 2022 | 33 | 1.150 |
Why?
|
| DNA Mutational Analysis | 14 | 2020 | 543 | 1.140 |
Why?
|
| Karyotyping | 19 | 2025 | 220 | 1.120 |
Why?
|
| Lymph Nodes | 18 | 2015 | 550 | 1.090 |
Why?
|
| Polymerase Chain Reaction | 25 | 2015 | 888 | 1.080 |
Why?
|
| Pathology, Clinical | 2 | 2017 | 38 | 1.000 |
Why?
|
| T-Lymphocytes | 11 | 2019 | 1276 | 0.990 |
Why?
|
| Adolescent | 55 | 2025 | 9550 | 0.990 |
Why?
|
| Epstein-Barr Virus Infections | 4 | 2020 | 59 | 0.970 |
Why?
|
| Proto-Oncogene Proteins c-kit | 6 | 2015 | 80 | 0.940 |
Why?
|
| Diagnosis, Differential | 29 | 2025 | 1519 | 0.930 |
Why?
|
| Gene Rearrangement | 11 | 2021 | 168 | 0.920 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2022 | 58 | 0.890 |
Why?
|
| Child, Preschool | 28 | 2021 | 3781 | 0.880 |
Why?
|
| Oncogene Proteins, Fusion | 9 | 2022 | 133 | 0.880 |
Why?
|
| Karyotype | 6 | 2023 | 34 | 0.870 |
Why?
|
| Child | 37 | 2025 | 7273 | 0.840 |
Why?
|
| Proto-Oncogene Proteins | 11 | 2019 | 663 | 0.830 |
Why?
|
| Janus Kinase 2 | 8 | 2024 | 59 | 0.820 |
Why?
|
| Chromosomes, Human, Pair 21 | 6 | 2015 | 53 | 0.810 |
Why?
|
| DNA-Binding Proteins | 11 | 2019 | 1231 | 0.810 |
Why?
|
| Pathology | 3 | 2020 | 36 | 0.780 |
Why?
|
| STAT3 Transcription Factor | 2 | 2014 | 87 | 0.780 |
Why?
|
| Young Adult | 33 | 2025 | 6922 | 0.770 |
Why?
|
| Splenic Diseases | 2 | 2020 | 12 | 0.760 |
Why?
|
| Neoplasms | 11 | 2023 | 3168 | 0.750 |
Why?
|
| Bone Marrow Neoplasms | 5 | 2018 | 18 | 0.750 |
Why?
|
| Mastocytosis, Systemic | 6 | 2025 | 13 | 0.740 |
Why?
|
| Leukemia, Large Granular Lymphocytic | 2 | 2013 | 2 | 0.740 |
Why?
|
| Immunoglobulin Heavy Chains | 10 | 2014 | 106 | 0.730 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 7 | 2020 | 175 | 0.720 |
Why?
|
| Flow Cytometry | 21 | 2017 | 710 | 0.710 |
Why?
|
| Chromosomes, Human, Pair 5 | 6 | 2026 | 113 | 0.690 |
Why?
|
| Ki-1 Antigen | 4 | 2013 | 19 | 0.680 |
Why?
|
| Vascular Neoplasms | 2 | 2020 | 21 | 0.680 |
Why?
|
| Bone Marrow Cells | 8 | 2015 | 264 | 0.680 |
Why?
|
| Splicing Factor U2AF | 2 | 2018 | 5 | 0.670 |
Why?
|
| Antigens, CD34 | 8 | 2014 | 161 | 0.660 |
Why?
|
| Killer Cells, Natural | 6 | 2021 | 287 | 0.660 |
Why?
|
| Hemangioma | 2 | 2020 | 62 | 0.650 |
Why?
|
| Gene Rearrangement, B-Lymphocyte | 4 | 2013 | 29 | 0.650 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 9 | 2022 | 203 | 0.640 |
Why?
|
| Hypereosinophilic Syndrome | 4 | 2023 | 6 | 0.630 |
Why?
|
| Proto-Oncogene Proteins B-raf | 4 | 2018 | 162 | 0.630 |
Why?
|
| In Situ Hybridization, Fluorescence | 22 | 2017 | 360 | 0.620 |
Why?
|
| B-Lymphocytes | 13 | 2017 | 703 | 0.610 |
Why?
|
| Disease-Free Survival | 12 | 2024 | 1171 | 0.610 |
Why?
|
| Spleen | 2 | 2020 | 372 | 0.600 |
Why?
|
| Phenotype | 16 | 2022 | 2545 | 0.590 |
Why?
|
| Consensus | 8 | 2025 | 366 | 0.580 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2019 | 61 | 0.580 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 11 | 2026 | 940 | 0.580 |
Why?
|
| Nuclear Proteins | 10 | 2023 | 740 | 0.570 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 2 | 2008 | 10 | 0.560 |
Why?
|
| Infant | 15 | 2018 | 3156 | 0.560 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2018 | 38 | 0.550 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 7 | 2022 | 132 | 0.550 |
Why?
|
| Retrospective Studies | 36 | 2025 | 10128 | 0.550 |
Why?
|
| Biopsy | 19 | 2020 | 1172 | 0.550 |
Why?
|
| Skin Neoplasms | 11 | 2019 | 621 | 0.550 |
Why?
|
| Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor | 3 | 2010 | 13 | 0.540 |
Why?
|
| Neoplasms, Second Primary | 6 | 2022 | 244 | 0.540 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 4 | 2011 | 111 | 0.530 |
Why?
|
| Sarcoma | 8 | 2005 | 220 | 0.490 |
Why?
|
| Primary Myelofibrosis | 4 | 2025 | 67 | 0.490 |
Why?
|
| DNA Methylation | 4 | 2015 | 699 | 0.480 |
Why?
|
| RNA Splicing Factors | 3 | 2024 | 30 | 0.480 |
Why?
|
| High-Throughput Nucleotide Sequencing | 6 | 2024 | 538 | 0.470 |
Why?
|
| Burkitt Lymphoma | 6 | 2003 | 32 | 0.470 |
Why?
|
| Hematology | 2 | 2018 | 32 | 0.460 |
Why?
|
| Genes, T-Cell Receptor gamma | 2 | 2008 | 4 | 0.460 |
Why?
|
| Clone Cells | 10 | 2025 | 219 | 0.460 |
Why?
|
| Neuroblastoma | 2 | 2009 | 394 | 0.460 |
Why?
|
| Granulocyte Precursor Cells | 2 | 2014 | 7 | 0.450 |
Why?
|
| Kaplan-Meier Estimate | 8 | 2024 | 874 | 0.450 |
Why?
|
| Cell Lineage | 8 | 2024 | 321 | 0.450 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 8 | 2016 | 184 | 0.450 |
Why?
|
| Phosphoproteins | 3 | 2024 | 258 | 0.440 |
Why?
|
| Neprilysin | 6 | 2003 | 39 | 0.440 |
Why?
|
| Abnormal Karyotype | 4 | 2023 | 8 | 0.430 |
Why?
|
| Epigenesis, Genetic | 2 | 2019 | 555 | 0.430 |
Why?
|
| Granuloma, Plasma Cell | 3 | 2001 | 8 | 0.430 |
Why?
|
| Lymphoma, AIDS-Related | 3 | 2002 | 7 | 0.430 |
Why?
|
| Bone Marrow Transplantation | 3 | 2014 | 281 | 0.430 |
Why?
|
| Anemia, Refractory, with Excess of Blasts | 1 | 2014 | 8 | 0.430 |
Why?
|
| Monosomy | 1 | 2014 | 12 | 0.430 |
Why?
|
| Tumor Virus Infections | 4 | 2015 | 83 | 0.420 |
Why?
|
| Protein-Tyrosine Kinases | 5 | 2008 | 302 | 0.410 |
Why?
|
| Receptors, Antigen, B-Cell | 7 | 2021 | 103 | 0.400 |
Why?
|
| Antigens, Neoplasm | 9 | 2001 | 356 | 0.400 |
Why?
|
| Liver Neoplasms | 4 | 2016 | 773 | 0.400 |
Why?
|
| Bone Marrow Diseases | 2 | 2013 | 37 | 0.390 |
Why?
|
| Chromosomes, Human, Pair 1 | 2 | 2006 | 102 | 0.380 |
Why?
|
| Polycythemia Vera | 2 | 2023 | 22 | 0.380 |
Why?
|
| Neoplasms, Multiple Primary | 5 | 2015 | 100 | 0.380 |
Why?
|
| Cadherins | 1 | 2014 | 180 | 0.380 |
Why?
|
| Receptors, CXCR4 | 1 | 2013 | 49 | 0.370 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 6 | 2007 | 147 | 0.370 |
Why?
|
| Arachidonate 12-Lipoxygenase | 1 | 2012 | 28 | 0.360 |
Why?
|
| Glutathione Transferase | 1 | 2012 | 115 | 0.360 |
Why?
|
| Antineoplastic Agents | 7 | 2024 | 2301 | 0.360 |
Why?
|
| Leukemia, Promyelocytic, Acute | 5 | 2017 | 47 | 0.360 |
Why?
|
| Paraffin Embedding | 12 | 2010 | 77 | 0.350 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 618 | 0.350 |
Why?
|
| Survival Analysis | 8 | 2024 | 1518 | 0.340 |
Why?
|
| Dendritic Cells, Follicular | 3 | 2008 | 20 | 0.340 |
Why?
|
| Basophils | 2 | 2024 | 26 | 0.340 |
Why?
|
| Thrombocythemia, Essential | 3 | 2025 | 16 | 0.330 |
Why?
|
| Herpesviridae Infections | 3 | 1996 | 15 | 0.330 |
Why?
|
| Genetic Predisposition to Disease | 7 | 2020 | 2465 | 0.330 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2011 | 113 | 0.330 |
Why?
|
| Peroxidase | 3 | 2001 | 54 | 0.330 |
Why?
|
| Anemia, Sideroblastic | 2 | 2024 | 5 | 0.320 |
Why?
|
| Abdominal Neoplasms | 2 | 2001 | 38 | 0.320 |
Why?
|
| Herpesvirus 8, Human | 2 | 2002 | 10 | 0.320 |
Why?
|
| Gene Rearrangement, T-Lymphocyte | 4 | 2006 | 18 | 0.320 |
Why?
|
| Multiple Myeloma | 3 | 2022 | 336 | 0.320 |
Why?
|
| Chromosomes, Human, Pair 3 | 4 | 2014 | 54 | 0.310 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2024 | 64 | 0.310 |
Why?
|
| DNA, Neoplasm | 11 | 2013 | 266 | 0.310 |
Why?
|
| Nose Neoplasms | 3 | 2002 | 36 | 0.300 |
Why?
|
| CCAAT-Enhancer-Binding Protein-alpha | 1 | 2009 | 6 | 0.300 |
Why?
|
| Antigens, CD20 | 8 | 2013 | 33 | 0.300 |
Why?
|
| Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative | 3 | 2021 | 3 | 0.290 |
Why?
|
| Blood Transfusion | 1 | 2010 | 171 | 0.290 |
Why?
|
| Chromosome Inversion | 4 | 2014 | 45 | 0.290 |
Why?
|
| Remission Induction | 6 | 2024 | 737 | 0.290 |
Why?
|
| Quality Assurance, Health Care | 1 | 2010 | 226 | 0.290 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 5 | 2016 | 23 | 0.280 |
Why?
|
| Dioxygenases | 3 | 2019 | 82 | 0.280 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2009 | 184 | 0.280 |
Why?
|
| Chromosomes, Human, Pair 8 | 4 | 2013 | 83 | 0.280 |
Why?
|
| Blast Crisis | 3 | 2020 | 37 | 0.270 |
Why?
|
| Cytogenetic Analysis | 4 | 2020 | 70 | 0.270 |
Why?
|
| Clostridium perfringens | 1 | 2007 | 7 | 0.270 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 2 | 2015 | 59 | 0.270 |
Why?
|
| Skin Diseases | 3 | 2010 | 173 | 0.270 |
Why?
|
| Germinal Center | 3 | 2015 | 62 | 0.270 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 4 | 2005 | 29 | 0.270 |
Why?
|
| Leukemia, B-Cell | 4 | 2010 | 22 | 0.270 |
Why?
|
| Neoplasm Staging | 6 | 2015 | 2009 | 0.270 |
Why?
|
| Hemolysis | 1 | 2007 | 60 | 0.260 |
Why?
|
| Histiocytic Sarcoma | 3 | 2016 | 7 | 0.260 |
Why?
|
| Chromosome Breakage | 1 | 2007 | 16 | 0.260 |
Why?
|
| In Situ Hybridization | 7 | 2015 | 303 | 0.260 |
Why?
|
| Chromosomes, Human, Pair 14 | 4 | 2015 | 50 | 0.260 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 9 | 2010 | 885 | 0.260 |
Why?
|
| California | 5 | 2018 | 157 | 0.260 |
Why?
|
| Lymphoproliferative Disorders | 4 | 2002 | 104 | 0.260 |
Why?
|
| Lymphocyte Activation | 2 | 2021 | 798 | 0.250 |
Why?
|
| beta Catenin | 1 | 2009 | 265 | 0.250 |
Why?
|
| Disease Models, Animal | 1 | 2014 | 2479 | 0.250 |
Why?
|
| Vimentin | 6 | 2002 | 47 | 0.250 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2006 | 45 | 0.250 |
Why?
|
| Hemangioendothelioma | 1 | 2006 | 9 | 0.250 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2006 | 42 | 0.240 |
Why?
|
| Dendritic Cell Sarcoma, Follicular | 3 | 2012 | 3 | 0.240 |
Why?
|
| Quality Improvement | 1 | 2010 | 482 | 0.240 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 12 | 2024 | 2543 | 0.240 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2006 | 78 | 0.230 |
Why?
|
| Philadelphia Chromosome | 1 | 2006 | 44 | 0.230 |
Why?
|
| Survival Rate | 6 | 2020 | 1945 | 0.230 |
Why?
|
| Clostridium Infections | 1 | 2007 | 126 | 0.230 |
Why?
|
| Cell Proliferation | 6 | 2019 | 1732 | 0.230 |
Why?
|
| Medical Records | 3 | 2015 | 121 | 0.230 |
Why?
|
| Sensitivity and Specificity | 9 | 2017 | 1909 | 0.230 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2006 | 550 | 0.230 |
Why?
|
| Neoplastic Stem Cells | 4 | 2015 | 172 | 0.230 |
Why?
|
| Biomarkers | 5 | 2022 | 1905 | 0.230 |
Why?
|
| Chromosomes, Human, Pair 11 | 2 | 2003 | 106 | 0.230 |
Why?
|
| Histiocytosis, Non-Langerhans-Cell | 1 | 2005 | 5 | 0.220 |
Why?
|
| Keratins | 3 | 2000 | 62 | 0.220 |
Why?
|
| Leukemia, T-Cell | 3 | 2010 | 17 | 0.220 |
Why?
|
| Transcription Factors | 6 | 2023 | 1687 | 0.220 |
Why?
|
| Mycosis Fungoides | 3 | 2011 | 30 | 0.220 |
Why?
|
| Genes, Immunoglobulin | 4 | 2013 | 61 | 0.210 |
Why?
|
| Castleman Disease | 2 | 2012 | 11 | 0.210 |
Why?
|
| Disseminated Intravascular Coagulation | 2 | 2017 | 29 | 0.210 |
Why?
|
| STAT5 Transcription Factor | 1 | 2024 | 44 | 0.210 |
Why?
|
| Practice Guidelines as Topic | 4 | 2019 | 1054 | 0.200 |
Why?
|
| Reproducibility of Results | 5 | 2017 | 2705 | 0.200 |
Why?
|
| Whole-Body Irradiation | 5 | 2020 | 70 | 0.200 |
Why?
|
| Predictive Value of Tests | 5 | 2017 | 1703 | 0.200 |
Why?
|
| Sarcoma, Endometrial Stromal | 2 | 2001 | 8 | 0.200 |
Why?
|
| Consolidation Chemotherapy | 2 | 2024 | 23 | 0.200 |
Why?
|
| Chromosomes, Human, Pair 18 | 3 | 2015 | 42 | 0.200 |
Why?
|
| Telomerase | 1 | 2003 | 67 | 0.200 |
Why?
|
| Antibodies, Monoclonal | 5 | 2007 | 1385 | 0.200 |
Why?
|
| Polycythemia | 1 | 2023 | 7 | 0.190 |
Why?
|
| Sarcoma, Myeloid | 1 | 2023 | 14 | 0.190 |
Why?
|
| Neoplasm, Residual | 1 | 2024 | 196 | 0.190 |
Why?
|
| Sarcoma, Kaposi | 1 | 2002 | 17 | 0.190 |
Why?
|
| Plasmacytoma | 1 | 2022 | 26 | 0.190 |
Why?
|
| Epstein-Barr Virus Nuclear Antigens | 1 | 2002 | 3 | 0.190 |
Why?
|
| Pleural Effusion, Malignant | 1 | 2002 | 15 | 0.190 |
Why?
|
| Chromosomes, Human, Pair 9 | 3 | 2018 | 80 | 0.180 |
Why?
|
| Synaptophysin | 3 | 2009 | 11 | 0.180 |
Why?
|
| Pleural Neoplasms | 1 | 2004 | 200 | 0.180 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2022 | 46 | 0.180 |
Why?
|
| Cytoplasm | 4 | 2009 | 275 | 0.180 |
Why?
|
| Transplantation Conditioning | 3 | 2020 | 383 | 0.180 |
Why?
|
| Isochromosomes | 1 | 2021 | 1 | 0.180 |
Why?
|
| Sialoglycoproteins | 2 | 1999 | 31 | 0.180 |
Why?
|
| Intestinal Neoplasms | 1 | 2002 | 68 | 0.180 |
Why?
|
| Cytarabine | 3 | 2020 | 217 | 0.180 |
Why?
|
| Breast Neoplasms | 4 | 2008 | 3155 | 0.180 |
Why?
|
| Biopsy, Needle | 4 | 2015 | 226 | 0.180 |
Why?
|
| Terminology as Topic | 2 | 2009 | 219 | 0.170 |
Why?
|
| Immunoblastic Lymphadenopathy | 2 | 2012 | 6 | 0.170 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2022 | 110 | 0.170 |
Why?
|
| Daunorubicin | 2 | 2020 | 77 | 0.170 |
Why?
|
| Mesothelioma | 1 | 2004 | 331 | 0.170 |
Why?
|
| Monocytes | 2 | 2017 | 214 | 0.170 |
Why?
|
| Chromosomes, Human, Pair 17 | 3 | 2005 | 108 | 0.170 |
Why?
|
| PubMed | 1 | 2020 | 16 | 0.160 |
Why?
|
| Ribonucleoprotein, U2 Small Nuclear | 2 | 2024 | 2 | 0.160 |
Why?
|
| Blood Cells | 1 | 2020 | 32 | 0.160 |
Why?
|
| Receptors, Thrombopoietin | 1 | 2020 | 4 | 0.160 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 2000 | 26 | 0.160 |
Why?
|
| Calreticulin | 1 | 2020 | 16 | 0.160 |
Why?
|
| Splenomegaly | 1 | 2020 | 19 | 0.160 |
Why?
|
| Intestine, Small | 1 | 2002 | 311 | 0.160 |
Why?
|
| CD79 Antigens | 7 | 2013 | 17 | 0.160 |
Why?
|
| Photopheresis | 1 | 2020 | 12 | 0.160 |
Why?
|
| Endometrial Neoplasms | 2 | 2001 | 226 | 0.160 |
Why?
|
| Plasma Cells | 3 | 2006 | 84 | 0.160 |
Why?
|
| Genetic Markers | 3 | 2016 | 469 | 0.160 |
Why?
|
| Monocyte-Macrophage Precursor Cells | 1 | 2020 | 4 | 0.160 |
Why?
|
| Core Binding Factors | 1 | 2020 | 12 | 0.160 |
Why?
|
| Aminopyridines | 1 | 2020 | 48 | 0.160 |
Why?
|
| Triazines | 1 | 2020 | 54 | 0.160 |
Why?
|
| Follow-Up Studies | 9 | 2014 | 3814 | 0.160 |
Why?
|
| Immunoenzyme Techniques | 8 | 2009 | 291 | 0.160 |
Why?
|
| PAX5 Transcription Factor | 2 | 2013 | 33 | 0.160 |
Why?
|
| Infant, Newborn | 4 | 2016 | 2427 | 0.160 |
Why?
|
| Carcinoma, Lobular | 1 | 2000 | 83 | 0.160 |
Why?
|
| Precancerous Conditions | 2 | 2019 | 204 | 0.150 |
Why?
|
| Panniculitis | 1 | 2019 | 11 | 0.150 |
Why?
|
| Genomics | 2 | 2022 | 848 | 0.150 |
Why?
|
| Adenocarcinoma | 3 | 2012 | 1171 | 0.150 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2002 | 202 | 0.150 |
Why?
|
| Hematopoietic Stem Cells | 3 | 2013 | 319 | 0.150 |
Why?
|
| Sequence Analysis, DNA | 2 | 2009 | 891 | 0.150 |
Why?
|
| Clinical Protocols | 2 | 2010 | 154 | 0.150 |
Why?
|
| Bone Neoplasms | 1 | 2002 | 308 | 0.150 |
Why?
|
| Giant Cells | 1 | 1999 | 18 | 0.150 |
Why?
|
| Immunoglobulin Light Chains | 2 | 2015 | 66 | 0.150 |
Why?
|
| Biological Products | 1 | 2021 | 178 | 0.150 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2001 | 424 | 0.150 |
Why?
|
| Cohort Studies | 4 | 2023 | 3044 | 0.150 |
Why?
|
| Gene Rearrangement, B-Lymphocyte, Heavy Chain | 5 | 2002 | 16 | 0.140 |
Why?
|
| Disease Progression | 8 | 2018 | 1529 | 0.140 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2019 | 87 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 1999 | 61 | 0.140 |
Why?
|
| Liver Transplantation | 2 | 2008 | 1193 | 0.140 |
Why?
|
| RNA, Messenger | 3 | 2009 | 2020 | 0.140 |
Why?
|
| Down Syndrome | 2 | 2016 | 50 | 0.140 |
Why?
|
| Polymorphism, Genetic | 1 | 2002 | 826 | 0.140 |
Why?
|
| Fusion Proteins, bcr-abl | 2 | 2018 | 110 | 0.140 |
Why?
|
| Proto-Oncogene Proteins A-raf | 1 | 2018 | 1 | 0.140 |
Why?
|
| Tissue Array Analysis | 4 | 2015 | 134 | 0.140 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2000 | 149 | 0.140 |
Why?
|
| Leukemia, Mast-Cell | 2 | 2010 | 5 | 0.140 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 3 | 2008 | 156 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 4 | 2007 | 42 | 0.140 |
Why?
|
| Skin | 2 | 2013 | 575 | 0.140 |
Why?
|
| ras Proteins | 3 | 2018 | 132 | 0.140 |
Why?
|
| Kidney Neoplasms | 2 | 2001 | 531 | 0.140 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2018 | 23 | 0.140 |
Why?
|
| Multi-Institutional Systems | 1 | 2018 | 3 | 0.140 |
Why?
|
| Erythroid Cells | 1 | 2018 | 16 | 0.140 |
Why?
|
| Graft vs Host Disease | 1 | 2020 | 365 | 0.140 |
Why?
|
| Proteins | 1 | 2003 | 790 | 0.140 |
Why?
|
| Mutation, Missense | 1 | 2019 | 296 | 0.140 |
Why?
|
| Mutation Rate | 1 | 2018 | 54 | 0.130 |
Why?
|
| Pathology, Surgical | 2 | 2010 | 13 | 0.130 |
Why?
|
| Decalcification Technique | 1 | 1997 | 2 | 0.130 |
Why?
|
| Gene Frequency | 3 | 2025 | 700 | 0.130 |
Why?
|
| Chromogranins | 3 | 2009 | 11 | 0.130 |
Why?
|
| Leukocyte Common Antigens | 3 | 2015 | 50 | 0.130 |
Why?
|
| Neoplasms, Vascular Tissue | 1 | 1997 | 3 | 0.130 |
Why?
|
| History, 21st Century | 1 | 2018 | 187 | 0.130 |
Why?
|
| Genotype | 4 | 2019 | 1866 | 0.130 |
Why?
|
| Colonic Neoplasms | 2 | 2012 | 578 | 0.130 |
Why?
|
| Chelating Agents | 1 | 1997 | 68 | 0.130 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2017 | 31 | 0.130 |
Why?
|
| Lymphangioma | 1 | 1997 | 15 | 0.130 |
Why?
|
| DNA | 3 | 2005 | 1260 | 0.130 |
Why?
|
| Specimen Handling | 2 | 2010 | 109 | 0.130 |
Why?
|
| Diagnostic Errors | 4 | 2010 | 156 | 0.130 |
Why?
|
| Histones | 1 | 2019 | 361 | 0.130 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2001 | 357 | 0.130 |
Why?
|
| Lymphocyte Subsets | 1 | 2017 | 68 | 0.130 |
Why?
|
| Blood Coagulation | 1 | 2017 | 90 | 0.120 |
Why?
|
| Antigens, Surface | 1 | 1997 | 97 | 0.120 |
Why?
|
| Age Factors | 3 | 2017 | 1898 | 0.120 |
Why?
|
| Cell Count | 2 | 2014 | 195 | 0.120 |
Why?
|
| Histiocytoma, Benign Fibrous | 1 | 1996 | 23 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 1996 | 85 | 0.120 |
Why?
|
| Stomach Neoplasms | 2 | 2015 | 305 | 0.120 |
Why?
|
| Immunoglobulins | 2 | 2013 | 122 | 0.120 |
Why?
|
| Genes, Neoplasm | 1 | 2016 | 39 | 0.120 |
Why?
|
| Cysts | 1 | 1997 | 99 | 0.120 |
Why?
|
| Aneuploidy | 2 | 1997 | 59 | 0.120 |
Why?
|
| Muscle Neoplasms | 1 | 2016 | 16 | 0.120 |
Why?
|
| Cytogenetics | 2 | 2015 | 27 | 0.120 |
Why?
|
| RNA, Neoplasm | 3 | 2003 | 86 | 0.120 |
Why?
|
| Histiocytosis | 1 | 2015 | 7 | 0.120 |
Why?
|
| Nuclear Receptor Coactivator 2 | 1 | 2015 | 16 | 0.120 |
Why?
|
| Antigens, CD19 | 3 | 2013 | 78 | 0.110 |
Why?
|
| Certification | 1 | 1996 | 58 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2015 | 26 | 0.110 |
Why?
|
| Molecular Biology | 1 | 1996 | 83 | 0.110 |
Why?
|
| Myeloid Cells | 1 | 2016 | 119 | 0.110 |
Why?
|
| Carcinoma, Signet Ring Cell | 2 | 2012 | 9 | 0.110 |
Why?
|
| Mediastinal Neoplasms | 1 | 2015 | 40 | 0.110 |
Why?
|
| Chromosome Deletion | 4 | 2023 | 213 | 0.110 |
Why?
|
| False Positive Reactions | 2 | 2009 | 212 | 0.110 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2015 | 19 | 0.110 |
Why?
|
| Pyridazines | 1 | 2015 | 21 | 0.110 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2015 | 40 | 0.110 |
Why?
|
| Proportional Hazards Models | 2 | 2014 | 888 | 0.110 |
Why?
|
| Neuroendocrine Tumors | 1 | 1997 | 136 | 0.110 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2015 | 691 | 0.110 |
Why?
|
| Treatment Outcome | 9 | 2024 | 9070 | 0.110 |
Why?
|
| Receptors, Complement 3d | 1 | 2015 | 14 | 0.110 |
Why?
|
| Repressor Proteins | 2 | 2017 | 443 | 0.110 |
Why?
|
| Fatal Outcome | 4 | 2010 | 292 | 0.110 |
Why?
|
| Microsatellite Instability | 2 | 2012 | 64 | 0.110 |
Why?
|
| LIM Domain Proteins | 1 | 2015 | 24 | 0.110 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 2015 | 31 | 0.110 |
Why?
|
| Ribonucleoproteins | 1 | 2014 | 36 | 0.110 |
Why?
|
| Pseudolymphoma | 1 | 2014 | 7 | 0.110 |
Why?
|
| Immunotherapy | 1 | 2020 | 762 | 0.110 |
Why?
|
| Risk | 2 | 2013 | 651 | 0.110 |
Why?
|
| Imidazoles | 1 | 2015 | 138 | 0.110 |
Why?
|
| Ileal Diseases | 1 | 2014 | 24 | 0.110 |
Why?
|
| Immunoglobulin M | 1 | 2015 | 152 | 0.110 |
Why?
|
| CD3 Complex | 3 | 2000 | 135 | 0.110 |
Why?
|
| Endosonography | 1 | 2015 | 100 | 0.100 |
Why?
|
| Antigen-Presenting Cells | 1 | 2015 | 146 | 0.100 |
Why?
|
| Cloning, Molecular | 2 | 2006 | 577 | 0.100 |
Why?
|
| Erythroblasts | 1 | 2014 | 27 | 0.100 |
Why?
|
| Blotting, Southern | 4 | 2002 | 107 | 0.100 |
Why?
|
| Carcinoma | 3 | 2005 | 439 | 0.100 |
Why?
|
| Octamer Transcription Factor-2 | 1 | 2013 | 3 | 0.100 |
Why?
|
| Agar | 1 | 1993 | 9 | 0.100 |
Why?
|
| Neoplasm Metastasis | 2 | 2009 | 1060 | 0.100 |
Why?
|
| Histological Techniques | 1 | 1993 | 33 | 0.100 |
Why?
|
| Gene Deletion | 1 | 2015 | 351 | 0.100 |
Why?
|
| Neutropenia | 2 | 2011 | 209 | 0.100 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 2 | 2013 | 37 | 0.100 |
Why?
|
| Cell Line, Tumor | 1 | 2019 | 2757 | 0.100 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2015 | 304 | 0.100 |
Why?
|
| Hemoglobinuria, Paroxysmal | 1 | 2013 | 6 | 0.100 |
Why?
|
| DNA Nucleotidylexotransferase | 1 | 2012 | 11 | 0.090 |
Why?
|
| Anemia, Aplastic | 1 | 2013 | 31 | 0.090 |
Why?
|
| United States | 7 | 2017 | 7581 | 0.090 |
Why?
|
| AIDS-Related Complex | 1 | 1992 | 1 | 0.090 |
Why?
|
| Sezary Syndrome | 2 | 2005 | 12 | 0.090 |
Why?
|
| Frizzled Receptors | 1 | 2012 | 14 | 0.090 |
Why?
|
| Combined Modality Therapy | 4 | 2009 | 1719 | 0.090 |
Why?
|
| Adenoma | 2 | 2012 | 258 | 0.090 |
Why?
|
| Antibody Specificity | 3 | 1998 | 126 | 0.090 |
Why?
|
| Soft Tissue Neoplasms | 3 | 1999 | 124 | 0.090 |
Why?
|
| Dendritic Cells | 2 | 2012 | 538 | 0.090 |
Why?
|
| Immunoglobulin kappa-Chains | 2 | 2009 | 60 | 0.090 |
Why?
|
| Gene Expression | 2 | 2015 | 1304 | 0.090 |
Why?
|
| Cells | 1 | 1992 | 30 | 0.090 |
Why?
|
| Lymphocyte Count | 2 | 2017 | 98 | 0.090 |
Why?
|
| Melanoma | 3 | 2002 | 494 | 0.090 |
Why?
|
| Ploidies | 1 | 1991 | 39 | 0.090 |
Why?
|
| Antigens, Differentiation | 2 | 1993 | 124 | 0.090 |
Why?
|
| CD56 Antigen | 2 | 2021 | 18 | 0.090 |
Why?
|
| Leukocyte Count | 2 | 2025 | 209 | 0.090 |
Why?
|
| Seminal Vesicles | 1 | 1991 | 39 | 0.090 |
Why?
|
| Lichen Planus | 1 | 2011 | 10 | 0.090 |
Why?
|
| Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 1 | 2011 | 16 | 0.090 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 1 | 2011 | 117 | 0.090 |
Why?
|
| Nerve Sheath Neoplasms | 1 | 2011 | 20 | 0.090 |
Why?
|
| Recurrence | 4 | 2024 | 1188 | 0.090 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2011 | 27 | 0.090 |
Why?
|
| RNA, Viral | 3 | 2000 | 285 | 0.090 |
Why?
|
| Dacarbazine | 1 | 2011 | 100 | 0.080 |
Why?
|
| Cell Division | 3 | 2003 | 689 | 0.080 |
Why?
|
| Vaginal Neoplasms | 1 | 2011 | 84 | 0.080 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 3 | 2023 | 177 | 0.080 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2011 | 134 | 0.080 |
Why?
|
| Trans-Activators | 1 | 2013 | 439 | 0.080 |
Why?
|
| Risk Assessment | 3 | 2025 | 2434 | 0.080 |
Why?
|
| Chromosome Disorders | 4 | 1998 | 97 | 0.080 |
Why?
|
| HLA-DR Antigens | 3 | 2009 | 56 | 0.080 |
Why?
|
| Blood Group Incompatibility | 1 | 2010 | 22 | 0.080 |
Why?
|
| Autoimmune Diseases | 1 | 2013 | 255 | 0.080 |
Why?
|
| Stromal Cells | 1 | 2011 | 152 | 0.080 |
Why?
|
| Splenectomy | 2 | 2010 | 46 | 0.080 |
Why?
|
| Antibodies | 2 | 2010 | 346 | 0.080 |
Why?
|
| Colonic Polyps | 1 | 2011 | 137 | 0.080 |
Why?
|
| ABO Blood-Group System | 1 | 2010 | 58 | 0.080 |
Why?
|
| Staining and Labeling | 2 | 2010 | 155 | 0.080 |
Why?
|
| Orbital Neoplasms | 1 | 2010 | 16 | 0.080 |
Why?
|
| Cell Cycle Proteins | 2 | 2003 | 409 | 0.080 |
Why?
|
| Immune System | 1 | 2011 | 101 | 0.080 |
Why?
|
| Lymphadenitis | 1 | 2010 | 7 | 0.080 |
Why?
|
| Genes, T-Cell Receptor | 1 | 2010 | 10 | 0.080 |
Why?
|
| Formaldehyde | 2 | 2002 | 51 | 0.080 |
Why?
|
| Orbit | 1 | 2010 | 36 | 0.080 |
Why?
|
| Cytological Techniques | 1 | 2009 | 30 | 0.080 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2010 | 43 | 0.080 |
Why?
|
| Referral and Consultation | 1 | 2013 | 373 | 0.080 |
Why?
|
| Pyrimidines | 2 | 2021 | 382 | 0.080 |
Why?
|
| Cell Differentiation | 2 | 2014 | 1611 | 0.080 |
Why?
|
| Risk Factors | 3 | 2025 | 5900 | 0.070 |
Why?
|
| Trisomy | 3 | 2003 | 53 | 0.070 |
Why?
|
| Frozen Sections | 4 | 2002 | 50 | 0.070 |
Why?
|
| Lymphoid Enhancer-Binding Factor 1 | 1 | 2009 | 13 | 0.070 |
Why?
|
| Head and Neck Neoplasms | 1 | 1996 | 1071 | 0.070 |
Why?
|
| Disease Management | 2 | 2025 | 357 | 0.070 |
Why?
|
| Lymphocytes | 3 | 1997 | 453 | 0.070 |
Why?
|
| Surveys and Questionnaires | 1 | 2017 | 2787 | 0.070 |
Why?
|
| Prostatic Neoplasms | 2 | 1997 | 1769 | 0.070 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2010 | 201 | 0.070 |
Why?
|
| Interphase | 2 | 2005 | 36 | 0.070 |
Why?
|
| Hematoxylin | 1 | 2008 | 8 | 0.070 |
Why?
|
| Eosine Yellowish-(YS) | 1 | 2008 | 13 | 0.070 |
Why?
|
| Carcinoma, Bronchogenic | 1 | 2008 | 11 | 0.070 |
Why?
|
| Leukosialin | 2 | 1999 | 16 | 0.070 |
Why?
|
| Colon | 1 | 2011 | 540 | 0.070 |
Why?
|
| Liver Failure, Acute | 1 | 2008 | 37 | 0.070 |
Why?
|
| Cryoglobulinemia | 1 | 2007 | 5 | 0.070 |
Why?
|
| Gene Amplification | 2 | 2015 | 139 | 0.070 |
Why?
|
| Enzyme Inhibitors | 2 | 2018 | 638 | 0.070 |
Why?
|
| DNA Probes | 2 | 2005 | 66 | 0.060 |
Why?
|
| Animals | 5 | 2014 | 27973 | 0.060 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 7 | 1 | 2006 | 4 | 0.060 |
Why?
|
| Leukemia, Plasma Cell | 1 | 2006 | 2 | 0.060 |
Why?
|
| Lymphoma, Large-Cell, Immunoblastic | 2 | 1997 | 3 | 0.060 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 1 | 2006 | 10 | 0.060 |
Why?
|
| Zinc Fingers | 1 | 2006 | 58 | 0.060 |
Why?
|
| Epithelium | 2 | 1998 | 314 | 0.060 |
Why?
|
| Intestinal Mucosa | 1 | 2011 | 825 | 0.060 |
Why?
|
| src Homology Domains | 1 | 2006 | 45 | 0.060 |
Why?
|
| Phosphopyruvate Hydratase | 2 | 1997 | 39 | 0.060 |
Why?
|
| Core Binding Factor beta Subunit | 1 | 2006 | 2 | 0.060 |
Why?
|
| Chronic Disease | 2 | 2003 | 941 | 0.060 |
Why?
|
| Transplantation, Homologous | 2 | 2025 | 1014 | 0.060 |
Why?
|
| Blood Cell Count | 1 | 2005 | 65 | 0.060 |
Why?
|
| Myosin Heavy Chains | 1 | 2006 | 86 | 0.060 |
Why?
|
| DNA Primers | 2 | 1997 | 528 | 0.060 |
Why?
|
| Data Collection | 1 | 2007 | 370 | 0.060 |
Why?
|
| Chromosomes, Artificial, Bacterial | 1 | 2005 | 32 | 0.060 |
Why?
|
| Patient Identification Systems | 1 | 2005 | 7 | 0.060 |
Why?
|
| Hyperplasia | 3 | 2013 | 146 | 0.060 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2006 | 99 | 0.060 |
Why?
|
| Hepatitis C | 1 | 2007 | 181 | 0.060 |
Why?
|
| Staurosporine | 1 | 2005 | 34 | 0.060 |
Why?
|
| Down-Regulation | 2 | 2022 | 523 | 0.060 |
Why?
|
| Collagen | 2 | 1997 | 301 | 0.060 |
Why?
|
| Aspartic Acid | 1 | 2005 | 62 | 0.060 |
Why?
|
| Platelet Count | 1 | 2025 | 90 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 15 | 2 | 2005 | 65 | 0.060 |
Why?
|
| Inflammation | 1 | 2011 | 1049 | 0.060 |
Why?
|
| Genetic Techniques | 1 | 2005 | 74 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2011 | 1339 | 0.050 |
Why?
|
| Eosinophils | 2 | 1997 | 194 | 0.050 |
Why?
|
| Paraffin | 2 | 2000 | 4 | 0.050 |
Why?
|
| Antibodies, Bispecific | 1 | 2024 | 37 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 7 | 3 | 2002 | 80 | 0.050 |
Why?
|
| Case-Control Studies | 4 | 2013 | 1925 | 0.050 |
Why?
|
| Actins | 2 | 1997 | 467 | 0.050 |
Why?
|
| Receptors, Cell Surface | 1 | 2005 | 291 | 0.050 |
Why?
|
| Liver | 3 | 2022 | 1206 | 0.050 |
Why?
|
| Colorectal Neoplasms | 1 | 2012 | 1054 | 0.050 |
Why?
|
| Induction Chemotherapy | 1 | 2024 | 146 | 0.050 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2022 | 27 | 0.050 |
Why?
|
| Postoperative Complications | 2 | 2005 | 2552 | 0.050 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2002 | 46 | 0.050 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2022 | 50 | 0.050 |
Why?
|
| Base Sequence | 2 | 1996 | 2207 | 0.050 |
Why?
|
| Fixatives | 1 | 2002 | 12 | 0.050 |
Why?
|
| HIV Seropositivity | 1 | 2002 | 49 | 0.050 |
Why?
|
| Blotting, Western | 2 | 2001 | 774 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2002 | 35 | 0.050 |
Why?
|
| Interleukin-2 | 1 | 2003 | 244 | 0.050 |
Why?
|
| Mucin-1 | 2 | 2011 | 46 | 0.050 |
Why?
|
| Ki-67 Antigen | 1 | 2002 | 66 | 0.050 |
Why?
|
| DNA Mismatch Repair | 2 | 2012 | 58 | 0.040 |
Why?
|
| Molecular Sequence Data | 2 | 1996 | 2889 | 0.040 |
Why?
|
| Neoplasms, Fibrous Tissue | 1 | 2001 | 2 | 0.040 |
Why?
|
| False Negative Reactions | 1 | 2001 | 59 | 0.040 |
Why?
|
| Stem Cell Transplantation | 1 | 2003 | 192 | 0.040 |
Why?
|
| Macrophages | 1 | 2005 | 609 | 0.040 |
Why?
|
| Laboratories | 1 | 2001 | 46 | 0.040 |
Why?
|
| Oncogene Fusion | 1 | 2021 | 10 | 0.040 |
Why?
|
| Leukemia, Megakaryoblastic, Acute | 1 | 2001 | 9 | 0.040 |
Why?
|
| Amino Acid Substitution | 1 | 2002 | 331 | 0.040 |
Why?
|
| Exons | 1 | 2023 | 447 | 0.040 |
Why?
|
| Cyclophosphamide | 3 | 2011 | 278 | 0.040 |
Why?
|
| Functional Laterality | 1 | 2002 | 204 | 0.040 |
Why?
|
| Receptors, Progesterone | 1 | 2002 | 195 | 0.040 |
Why?
|
| Piperazines | 1 | 2003 | 284 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 2001 | 51 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2005 | 603 | 0.040 |
Why?
|
| Nitriles | 1 | 2021 | 154 | 0.040 |
Why?
|
| Reed-Sternberg Cells | 1 | 2000 | 4 | 0.040 |
Why?
|
| Leiomyosarcoma | 1 | 2001 | 48 | 0.040 |
Why?
|
| Pentostatin | 1 | 2020 | 13 | 0.040 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2000 | 24 | 0.040 |
Why?
|
| Pyrazoles | 1 | 2021 | 152 | 0.040 |
Why?
|
| Gastrointestinal Tract | 1 | 2022 | 196 | 0.040 |
Why?
|
| Genes, erbB-2 | 1 | 2000 | 25 | 0.040 |
Why?
|
| Receptors, Estrogen | 1 | 2002 | 412 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2022 | 290 | 0.040 |
Why?
|
| Receptor, ErbB-2 | 1 | 2002 | 280 | 0.040 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2002 | 298 | 0.040 |
Why?
|
| MART-1 Antigen | 1 | 2000 | 21 | 0.040 |
Why?
|
| Observer Variation | 1 | 2001 | 570 | 0.040 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2000 | 40 | 0.040 |
Why?
|
| Viruses | 1 | 2000 | 64 | 0.040 |
Why?
|
| Sjogren's Syndrome | 1 | 2000 | 34 | 0.040 |
Why?
|
| Mice, SCID | 1 | 2000 | 271 | 0.040 |
Why?
|
| Phospholipase C gamma | 1 | 2019 | 14 | 0.040 |
Why?
|
| Skin Physiological Phenomena | 1 | 2019 | 18 | 0.040 |
Why?
|
| Thymus Neoplasms | 1 | 2000 | 46 | 0.040 |
Why?
|
| Methotrexate | 1 | 2020 | 226 | 0.040 |
Why?
|
| Cyclosporine | 1 | 2020 | 240 | 0.040 |
Why?
|
| Guidelines as Topic | 1 | 2020 | 163 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2000 | 573 | 0.040 |
Why?
|
| Allografts | 1 | 2020 | 205 | 0.040 |
Why?
|
| Tissue Embedding | 1 | 1999 | 6 | 0.040 |
Why?
|
| Cell Line | 2 | 2001 | 2458 | 0.040 |
Why?
|
| Pathology, Molecular | 1 | 2019 | 34 | 0.040 |
Why?
|
| France | 1 | 1999 | 52 | 0.040 |
Why?
|
| Chromosome Banding | 1 | 1999 | 66 | 0.040 |
Why?
|
| Tacrolimus | 1 | 2020 | 372 | 0.040 |
Why?
|
| Organ Transplantation | 1 | 2002 | 295 | 0.040 |
Why?
|
| Amino Acid Sequence | 1 | 2002 | 1994 | 0.040 |
Why?
|
| Stem Cells | 1 | 2001 | 386 | 0.040 |
Why?
|
| United Kingdom | 1 | 1999 | 189 | 0.040 |
Why?
|
| Congresses as Topic | 1 | 2019 | 121 | 0.030 |
Why?
|
| Mesenchymoma | 1 | 1998 | 4 | 0.030 |
Why?
|
| Seminiferous Tubules | 1 | 1998 | 8 | 0.030 |
Why?
|
| Methods | 1 | 1998 | 135 | 0.030 |
Why?
|
| Leukemia, Monocytic, Acute | 1 | 1998 | 9 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2019 | 300 | 0.030 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2015 | 392 | 0.030 |
Why?
|
| Chromogranin A | 1 | 1997 | 8 | 0.030 |
Why?
|
| Kidney Tubules | 1 | 1998 | 91 | 0.030 |
Why?
|
| Hemangiosarcoma | 1 | 1997 | 16 | 0.030 |
Why?
|
| Classification | 1 | 1998 | 55 | 0.030 |
Why?
|
| Serine-Arginine Splicing Factors | 1 | 2017 | 6 | 0.030 |
Why?
|
| Coloring Agents | 1 | 1997 | 65 | 0.030 |
Why?
|
| CD13 Antigens | 1 | 1997 | 5 | 0.030 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 3 | 1 | 1997 | 8 | 0.030 |
Why?
|
| Erythrocytes, Abnormal | 1 | 2017 | 11 | 0.030 |
Why?
|
| Leiomyoma | 1 | 2001 | 211 | 0.030 |
Why?
|
| Blood Coagulation Tests | 1 | 2017 | 31 | 0.030 |
Why?
|
| Hamartoma | 1 | 1997 | 33 | 0.030 |
Why?
|
| Bowen's Disease | 1 | 1997 | 9 | 0.030 |
Why?
|
| Vulvar Neoplasms | 1 | 1997 | 19 | 0.030 |
Why?
|
| Leukemia, Hairy Cell | 1 | 1997 | 72 | 0.030 |
Why?
|
| Uterine Neoplasms | 1 | 2001 | 277 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 1996 | 64 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 1997 | 127 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2000 | 1447 | 0.030 |
Why?
|
| HLA Antigens | 1 | 1998 | 228 | 0.030 |
Why?
|
| DNA Nucleotidyltransferases | 1 | 1996 | 32 | 0.030 |
Why?
|
| Membrane Glycoproteins | 2 | 2002 | 443 | 0.030 |
Why?
|
| Genes, Immunoglobulin Heavy Chain | 1 | 2016 | 9 | 0.030 |
Why?
|
| DNA, Viral | 1 | 1997 | 234 | 0.030 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 1996 | 42 | 0.030 |
Why?
|
| Iron | 1 | 1997 | 173 | 0.030 |
Why?
|
| Breast | 1 | 1998 | 302 | 0.030 |
Why?
|
| Leukocytes | 1 | 2017 | 210 | 0.030 |
Why?
|
| Gene Fusion | 1 | 2016 | 40 | 0.030 |
Why?
|
| Cyclins | 1 | 1996 | 80 | 0.030 |
Why?
|
| Cyclin D1 | 1 | 1996 | 85 | 0.030 |
Why?
|
| Chromosome Mapping | 1 | 1999 | 1051 | 0.030 |
Why?
|
| Oncogene Proteins | 1 | 1996 | 65 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2008 | 2363 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2019 | 564 | 0.030 |
Why?
|
| CD2 Antigens | 1 | 2015 | 22 | 0.030 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2015 | 62 | 0.030 |
Why?
|
| Hematemesis | 1 | 2015 | 3 | 0.030 |
Why?
|
| CREB-Binding Protein | 1 | 2015 | 16 | 0.030 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2015 | 38 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 3 | 2002 | 1022 | 0.030 |
Why?
|
| Rare Diseases | 1 | 2015 | 71 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2015 | 151 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 1996 | 314 | 0.030 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2015 | 171 | 0.030 |
Why?
|
| Leukocytosis | 1 | 2014 | 15 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 1996 | 512 | 0.030 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2014 | 69 | 0.030 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 1997 | 376 | 0.030 |
Why?
|
| Leukemia, Prolymphocytic, T-Cell | 1 | 1993 | 4 | 0.030 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 2 | 1 | 2013 | 7 | 0.030 |
Why?
|
| Mucous Membrane | 1 | 1994 | 82 | 0.030 |
Why?
|
| Cell Aggregation | 1 | 1993 | 36 | 0.030 |
Why?
|
| Paraproteinemias | 1 | 1993 | 19 | 0.020 |
Why?
|
| Microfilament Proteins | 1 | 2015 | 208 | 0.020 |
Why?
|
| Blood Platelets | 1 | 2014 | 149 | 0.020 |
Why?
|
| Patient Outcome Assessment | 1 | 2014 | 85 | 0.020 |
Why?
|
| Lymphocele | 1 | 1992 | 6 | 0.020 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2013 | 74 | 0.020 |
Why?
|
| Phagocytosis | 1 | 2013 | 111 | 0.020 |
Why?
|
| MutS Homolog 3 Protein | 1 | 2012 | 1 | 0.020 |
Why?
|
| Colon, Sigmoid | 1 | 2012 | 7 | 0.020 |
Why?
|
| Chemoradiotherapy | 1 | 2015 | 327 | 0.020 |
Why?
|
| Incidence | 2 | 1994 | 1697 | 0.020 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2012 | 50 | 0.020 |
Why?
|
| Diploidy | 1 | 1991 | 34 | 0.020 |
Why?
|
| Chromatin | 1 | 2015 | 440 | 0.020 |
Why?
|
| Ohio | 1 | 2011 | 42 | 0.020 |
Why?
|
| Electrosurgery | 1 | 2011 | 10 | 0.020 |
Why?
|
| Prednisolone | 1 | 2011 | 36 | 0.020 |
Why?
|
| Granulomatous Disease, Chronic | 1 | 2011 | 8 | 0.020 |
Why?
|
| Vincristine | 1 | 2011 | 100 | 0.020 |
Why?
|
| Rectum | 1 | 2012 | 148 | 0.020 |
Why?
|
| Age of Onset | 1 | 2012 | 341 | 0.020 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2011 | 35 | 0.020 |
Why?
|
| Prostate | 1 | 1994 | 416 | 0.020 |
Why?
|
| Reference Values | 1 | 1992 | 603 | 0.020 |
Why?
|
| Delivery, Obstetric | 1 | 2011 | 120 | 0.020 |
Why?
|
| Myelopoiesis | 1 | 2010 | 12 | 0.020 |
Why?
|
| Urticaria | 1 | 2010 | 15 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2011 | 283 | 0.020 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2011 | 148 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2012 | 570 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2012 | 505 | 0.020 |
Why?
|
| Cell Cycle | 1 | 1991 | 515 | 0.020 |
Why?
|
| Etoposide | 2 | 2000 | 205 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 2 | 2000 | 241 | 0.020 |
Why?
|
| Preleukemia | 1 | 2009 | 10 | 0.020 |
Why?
|
| Cell Separation | 1 | 2009 | 199 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2017 | 2484 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2010 | 944 | 0.020 |
Why?
|
| Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Protein | 1 | 2008 | 7 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2011 | 958 | 0.020 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2010 | 188 | 0.020 |
Why?
|
| Cell Transdifferentiation | 1 | 2008 | 13 | 0.020 |
Why?
|
| Caspases | 1 | 2008 | 151 | 0.020 |
Why?
|
| Cryoglobulins | 1 | 2007 | 4 | 0.020 |
Why?
|
| Sequence Deletion | 1 | 2008 | 206 | 0.020 |
Why?
|
| Time Factors | 1 | 2016 | 5380 | 0.020 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2008 | 165 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2006 | 158 | 0.020 |
Why?
|
| Palatine Tonsil | 2 | 1996 | 31 | 0.010 |
Why?
|
| Societies, Medical | 1 | 2010 | 618 | 0.010 |
Why?
|
| Subcellular Fractions | 1 | 2006 | 83 | 0.010 |
Why?
|
| Graft Survival | 2 | 2000 | 939 | 0.010 |
Why?
|
| Busulfan | 1 | 2005 | 41 | 0.010 |
Why?
|
| Protein Array Analysis | 1 | 2005 | 53 | 0.010 |
Why?
|
| Pregnancy | 1 | 2011 | 3128 | 0.010 |
Why?
|
| Mice | 2 | 2013 | 12230 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2006 | 601 | 0.010 |
Why?
|
| Idarubicin | 1 | 2003 | 8 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2009 | 1517 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2003 | 40 | 0.010 |
Why?
|
| Gene Rearrangement, B-Lymphocyte, Light Chain | 1 | 2002 | 15 | 0.010 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 1 | 2002 | 13 | 0.010 |
Why?
|
| Syndecans | 1 | 2002 | 4 | 0.010 |
Why?
|
| Imatinib Mesylate | 1 | 2003 | 127 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2005 | 1129 | 0.010 |
Why?
|
| Syndecan-1 | 1 | 2002 | 18 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2003 | 217 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2002 | 78 | 0.010 |
Why?
|
| Proteoglycans | 1 | 2002 | 75 | 0.010 |
Why?
|
| Rituximab | 1 | 2002 | 129 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2002 | 291 | 0.010 |
Why?
|
| CD5 Antigens | 1 | 2001 | 13 | 0.010 |
Why?
|
| Benzamides | 1 | 2003 | 246 | 0.010 |
Why?
|
| Collagen Type IV | 1 | 2001 | 28 | 0.010 |
Why?
|
| Histocytochemistry | 1 | 2001 | 121 | 0.010 |
Why?
|
| Cerebellar Diseases | 1 | 2000 | 22 | 0.010 |
Why?
|
| Chromosomes, Human | 1 | 2000 | 65 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2005 | 2827 | 0.010 |
Why?
|
| Leukemia, Radiation-Induced | 1 | 2000 | 12 | 0.010 |
Why?
|
| Archives | 1 | 2000 | 2 | 0.010 |
Why?
|
| Mice, Inbred NOD | 1 | 2000 | 218 | 0.010 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2000 | 52 | 0.010 |
Why?
|
| Receptors, Antigen | 1 | 1999 | 13 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2011 | 3450 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2002 | 456 | 0.010 |
Why?
|
| Histocytological Preparation Techniques | 1 | 1999 | 2 | 0.010 |
Why?
|
| Antigens | 1 | 2000 | 223 | 0.010 |
Why?
|
| Fetus | 1 | 2000 | 234 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 2000 | 371 | 0.010 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 1 | 1998 | 15 | 0.010 |
Why?
|
| Serologic Tests | 1 | 1999 | 40 | 0.010 |
Why?
|
| Thorax | 1 | 1999 | 77 | 0.010 |
Why?
|
| Axilla | 1 | 1999 | 109 | 0.010 |
Why?
|
| Surface Properties | 1 | 1998 | 126 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2000 | 709 | 0.010 |
Why?
|
| Radiotherapy | 1 | 2000 | 319 | 0.010 |
Why?
|
| Sex Chromosome Aberrations | 1 | 1997 | 19 | 0.010 |
Why?
|
| Y Chromosome | 1 | 1997 | 29 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2000 | 984 | 0.010 |
Why?
|
| Logistic Models | 1 | 2000 | 1240 | 0.010 |
Why?
|
| Sepsis | 1 | 2000 | 382 | 0.010 |
Why?
|
| Urinary Bladder | 1 | 1997 | 257 | 0.010 |
Why?
|
| Tissue Donors | 1 | 1999 | 541 | 0.010 |
Why?
|
| Prostatectomy | 1 | 1994 | 472 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2000 | 2562 | 0.000 |
Why?
|
| Prevalence | 1 | 1994 | 1318 | 0.000 |
Why?
|